Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A 12-month phase 3 study of pasireotide in Cushing's disease.

A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012 Mar 08; 366(10):914-24.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.